Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

JE, Cortes; HM, Kantarjian; TH, Brümmendorf; DW, Kim; AG, Turkina; ZX, Shen; R, Pasquini; HJ, Khoury; S, Arkin; A, Volkert; N, Besson; R, Abbas; J, Wang; E, Leip; C, Gambacorti-Passerini

doi:10.1182/blood-2011-05-355594

Public

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Shared by NobleBlocks on Aug 24, 2011 • 12:00 AM UTC

Authors:

Cortes JE

Kantarjian HM

Brümmendorf TH

Abstract

Bosutinib, a dual Src/Abl kinase inhibitor, has shown potent activity against chronic myeloid leukemia (CML). In this phase 1/2 study we evaluated bosutinib in patients with chronic phase imatinib-resistant or imatinib-intolerant CML. Part 1 was a dose-escalation study to determine the recommended s...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!